A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety Of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARSCov- 2 Infection in Household Contacts of Individuals Infected with SARS-CoV-2
|Effective start/end date||9/1/20 → 9/30/25|
- Regeneron Pharmaceuticals, Inc.
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.